This document reports on a study examining the use of mycophenolate mofetil (MMF) for treating primary glomerulonephritis. Four patients with focal segmental glomerulosclerosis (FSGS) or membranous nephropathy received MMF for at least 6 months. Results showed reduced urine protein levels and improved or stable kidney function in most patients, suggesting MMF may be useful for treating these conditions. However, larger randomized controlled trials are still needed to validate MMF's efficacy.
Difference Between Skeletal Smooth and Cardiac Muscles
Mycophenolate Mofetil in Primary Glomerulonephritis
1. MYCOPHENOLATE MOFETIL IN THE TREATMENT OF PRIMARY GLOMERULONEPHRITIS Chow YW, Yahya R, Visvanathan R Department of Nephrology, Kuala Lumpur Hospital
2. Objective Patients with primary glomerulonephritis (GN) Steroids or Cytotoxic agents Treatment resistance Frequent relapses
3.
4. Design & Methods Four patients Focal Segmental Glomerulosclerosis (FSGS) Membranous nephropathy (MN) 3 1 Partial Response to Steroids and Cyclosporine Steroid Resistance No Response to Steroids and Cyclophosphamide 1 2 1